Literature DB >> 27844181

STARD13 promotes hepatocellular carcinoma apoptosis by acting as a ceRNA for Fas.

Hai Zhang1, Fang Wang1, Yahua Hu2.   

Abstract

OBJECTIVES: To study the roles of STARD13 in cellular apoptosis of hepatocellular carcinoma (HCC).
RESULTS: Quantitative real-time PCR and immunohistochemistry analyses showed that the expression levels of STARD13 and Fas were lower in clinical HCC tissues than in normal tissues and were positively correlated, which is consistent with the results analyzed by The Cancer Genome Atlas (TCGA) data. Patients with higher STARD13 or Fas expression levels had longer overall survival. Additionally, STARD13 3'-UTR enhanced cellular apoptosis and the 3'-UTRs of STARD13 and Fas were predicted to harbor nine similar miRNA binding sites. And STARD13 3'-UTR promoted Fas expression in a 3'-UTR- and miRNA-dependent way and increased the sensitivity of HCC cells to chemotherapy. Importantly, the coding sequence of STARD13 did not increase Fas expression.
CONCLUSIONS: STARD13 3'-UTR promotes HCC apoptosis through acting as a ceRNA for Fas.

Entities:  

Keywords:  3′-UTR; Apoptosis; Fas; Hepatocellular carcinoma; STARD13; Tumor suppression; ceRNA

Mesh:

Substances:

Year:  2016        PMID: 27844181     DOI: 10.1007/s10529-016-2253-6

Source DB:  PubMed          Journal:  Biotechnol Lett        ISSN: 0141-5492            Impact factor:   2.461


  14 in total

1.  RNA-binding protein PUM2 suppresses osteosarcoma progression via partly and competitively binding to STARD13 3'UTR with miRNAs.

Authors:  Ruixi Hu; Xiaodong Zhu; Chao Chen; Ruijun Xu; Yifan Li; Wei Xu
Journal:  Cell Prolif       Date:  2018-08-07       Impact factor: 6.831

Review 2.  StarD13: a potential star target for tumor therapeutics.

Authors:  Leila Jaafar; Zeinab Chamseddine; Mirvat El-Sibai
Journal:  Hum Cell       Date:  2020-04-09       Impact factor: 4.174

Review 3.  Chemotherapy for hepatocellular carcinoma: The present and the future.

Authors:  Marco Le Grazie; Maria Rosa Biagini; Mirko Tarocchi; Simone Polvani; Andrea Galli
Journal:  World J Hepatol       Date:  2017-07-28

4.  StarD13 differentially regulates migration and invasion in prostate cancer cells.

Authors:  Leila Jaafar; Isabelle Fakhoury; Sahar Saab; Layal El-Hajjar; Wassim Abou-Kheir; Mirvat El-Sibai
Journal:  Hum Cell       Date:  2021-01-09       Impact factor: 4.174

5.  MiR-887-3p Negatively Regulates STARD13 and Promotes Pancreatic Cancer Progression.

Authors:  Xiaobo Xu; Shusen Zheng
Journal:  Cancer Manag Res       Date:  2020-07-22       Impact factor: 3.989

6.  Gut microbiome disruption altered the biotransformation and liver toxicity of arsenic in mice.

Authors:  Liang Chi; Jingchuan Xue; Pengcheng Tu; Yunjia Lai; Hongyu Ru; Kun Lu
Journal:  Arch Toxicol       Date:  2018-10-24       Impact factor: 5.153

Review 7.  StarD13 negatively regulates invadopodia formation and invasion in high-grade serous (HGS) ovarian adenocarcinoma cells by inhibiting Cdc42.

Authors:  Sandra Abdellatef; Isabelle Fakhoury; Maria Al Haddad; Leila Jaafar; Hiba Maalouf; Samer Hanna; Bassem Khalil; Zeinab El Masri; Louis Hodgson; Mirvat El-Sibai
Journal:  Eur J Cell Biol       Date:  2021-12-21       Impact factor: 4.492

Review 8.  Behind the curtain of non-coding RNAs; long non-coding RNAs regulating hepatocarcinogenesis.

Authors:  Aya El Khodiry; Menna Afify; Hend M El Tayebi
Journal:  World J Gastroenterol       Date:  2018-02-07       Impact factor: 5.742

9.  Homeobox B4 inhibits breast cancer cell migration by directly binding to StAR-related lipid transfer domain protein 13.

Authors:  Guangqi Zhou; Xinmei Liu; Bin Xiong; Yufang Sun
Journal:  Oncol Lett       Date:  2017-08-25       Impact factor: 2.967

10.  Pre-B cell leukemia transcription factor 3 induces inflammatory responses in human umbilical vein endothelial cells and murine sepsis via acting a competing endogenous RNA for high mobility group box 1 protein.

Authors:  Yunzhong Zhang; Jing Feng; Jizhen Cui; Guozheng Yang; Xianai Zhu
Journal:  Mol Med Rep       Date:  2018-02-15       Impact factor: 2.952

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.